Huntingtin proline-rich region modulation of Huntington's disease pathogenesis
Huntingtin proline-rich region modulation of Huntington's disease pathogenesis
批准号:
8838533
负责人:
Scott Zeitlin
金额:
$34.56万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-22 至 2019-06-30
关键词:
AffectAffinityAgeAge-MonthsAllelesAnimal ModelAntibodiesAutophagocytosisBehaviorBehavioralBindingBrainC-terminalCell modelCell physiologyCorpus striatum structureDataDeletion MutationDisease modelEvolutionExhibitsGene ExpressionGene Expression ProfileGene Expression ProfilingGene TargetingGenesHealthHumanHuntington DiseaseImageIn VitroKnock-in MouseLearningLifeMammalsMass Spectrum AnalysisMicrotubulesMolecular ConformationMusN-terminalNeurodegenerative DisordersNeuronsOrganellesPathogenesisPathway interactionsPhenotypePopulationProline-Rich DomainProsencephalonProteinsProteomicsRoleScaffolding ProteinStretchingTertiary Protein StructureTestingTimeToxic effectTrinucleotide RepeatsYeast Model SystemYeastsbasehuman Huntingtin proteinin vivomouse modelmutantneuron lossneuropathologypolyglutaminepostnatalprotein aggregateprotein degradationresearch studytherapeutic targettranscriptome sequencing
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): In Huntington's disease (HD), flanking protein domains modulate the toxicity of mutant Huntingtin's (HTT''s) expanded polyQ stretch. In mammals, a proline-rich region (PRR) is located at the C-terminal end of the polyQ stretch, and it has co-evolved with the polyQ stretch, increasing in size as the normal HTT polyQ stretch has lengthened during evolution. In yeast model systems, deletion of the HTT PRR in the context of an expanded polyQ stretch interferes with aggresome formation and increases toxicity of an N-terminal fragment of mutant HTT. To determine the role of the HTT PRR in modulating mutant HTT pathogenesis in mouse models for HD, we have generated three knock-in alleles of the mouse HD gene (Hdh) that express normal or mutant huntingtin (htt ) with deletions of the PRR - HdhΔP, Hdh140QΔP, and Hdh3xFlag140QΔP. We have found, in contrast to the results of the yeast studies, that deletion of the mutant htt PRR ameliorates several phenotypes exhibited by the CAG140 knock-in mouse model for HD, resulting in a significant delay in aggregate formation, alterations in aggregate conformation, normalization of striatal Darpp-32 expression, and the rescue of activity deficits. Using these new mouse models, we propose three complementary aims to determine the mechanisms by which deletion of the htt PRR affects HD mouse model pathogenesis. In Aim 1, we will test the hypothesis that deletion of the PRR modulates mutant htt's toxicity by altering the association of htt-interacting proteins. We propose
using anti-FLAG immunoaffinity purification to enrich for proteins associating with 3xFlag140QΔP- tt and 3xFlag140Q-htt in the striatum and cortex, and characterize their identity using mass spectrometry. In addition, we will characterize the protein composition of htt aggregates purified from the Hdh140Q/+ and Hdh140QΔP/+ brain to determine if differential sequestration of cellular proteins by 140Q-htt and 140QΔP-htt aggregates contributes to pathogenesis. In Aim 2, we will test the hypothesis that deletion of the mutant htt PRR alleviates mutant htt's perturbation of gene expression by performing RNA-seq analysis of wild-type, Hdh140Q/+, and Hdh140QΔP/+ striatal gene expression to identify those genes whose expression is altered in the Hdh140Q/+ brain but restored by the mutant htt PRR deletion in the Hdh140QΔP/+ brain. In Aim 3, we will genetically test the role of the htt PRR on aggresome formation (in cis or in trans), and the potential difference between the murine and human PRR in HD pathogenesis by characterizing behavior and neuropathology in Hdh140QΔP/ΔP, Hdh140QΔP/+, Hdh140QΔP/7QhuPRR and Hdh140QΔP/20QhuPRR mice as they age. In addition, we will characterize microtubule-based transport and autophagy (two pathways involved in aggresome formation and protein degradation) in early postnatal (P5) primary cortical and striatal neuronal cultures generated from wild-type, HdhΔP/ΔP, Hdh140Q/140Q and Hdh140QΔP/140QΔP mice.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding the mechanisms that modulate the effects of mutant Huntingtin lowering in aging Huntington's disease model mice
-
批准号:10556339
-
项目类别:
-
资助金额:$41.5万
-
财政年份:2022
-
负责人:Scott Zeitlin
-
依托单位:
Understanding the mechanisms that modulate the effects of mutant Huntingtin lowering in aging Huntington's disease model mice
-
批准号:10340336
-
项目类别:
-
资助金额:$41.5万
-
财政年份:2022
-
负责人:Scott Zeitlin
-
依托单位:
Modeling the effects of reducing huntingtin and Hdh alternative splicing in mice
-
批准号:8911911
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2015
-
负责人:Scott Zeitlin
-
依托单位:
Huntingtin proline-rich region modulation of Huntington's disease pathogenesis
-
批准号:9313949
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2014
-
负责人:Scott Zeitlin
-
依托单位:
Huntingtin proline-rich region modulation of Huntington's disease pathogenesis
-
批准号:9109070
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2014
-
负责人:Scott Zeitlin
-
依托单位:
Huntingtin proline-rich region modulation of Huntington's disease pathogenesis
-
批准号:8932828
-
项目类别:
-
资助金额:$34.56万
-
财政年份:2014
-
负责人:Scott Zeitlin
-
依托单位:
Reversible conditional models for Huntington's disease
-
批准号:8223374
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2011
-
负责人:Scott Zeitlin
-
依托单位:
Reversible conditional models for Huntington's disease
-
批准号:8323915
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2011
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:6862649
-
项目类别:
-
资助金额:$31.64万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:7194241
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:6617512
-
项目类别:
-
资助金额:$31.04万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's Disease
-
批准号:8416970
-
项目类别:
-
资助金额:$31.86万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's Disease
-
批准号:7781699
-
项目类别:
-
资助金额:$33.49万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's Disease
-
批准号:8015208
-
项目类别:
-
资助金额:$32.8万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:7027007
-
项目类别:
-
资助金额:$30.89万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:6701761
-
项目类别:
-
资助金额:$31.64万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's Disease
-
批准号:8220937
-
项目类别:
-
资助金额:$33.01万
-
财政年份:2003
-
负责人:Scott Zeitlin
-
依托单位:
Loss-of-function mechanisms in Huntington's disease
-
批准号:7687132
-
项目类别:
-
资助金额:$34.09万
-
财政年份:2002
-
负责人:Scott Zeitlin
-
依托单位:
海外基金